

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	Attorney Docket No. PU3375USW	International Appln. No. PCT/EP98/06278
	APPLICANT MANGEL, et al.	
	International Filing Date October 5, 1998	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page ____

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
PS	BK W089 09217A	5 Oct 1989	PCT			
PS	BL EP 0336759 A	11 Oct 1989	EP			
PS	BM EP 0254584A	27 Jan 1988	EP			
PS	BN EP 0279512A	24 Aug 1988	EP			
PS	BO EP 0315390A	10 May 1989	EP			
PS	BP WO94 01095A	20 Jan 1994	PCT			
PS	BQ EP 0306323 A	8 Mar 1989	EP			

Continue on page ____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

PS	CK	A. R. Northcutt et al., "Alosetron, A5HT3-Receptor Antagonist, Is Effective in the Treatment of Female Irritable Bowel Syndrome Patients" GASTROENTEROLOGY, Vol. 114, no. 4 Part 2, April 1998, page A812

Continue on page ____

EXAMINER <i>Phyllis Spivack</i>	DATE CONSIDERED 8/25/00
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	Attorney Docket No. PU3375USW	International Appln. No. PCT/EP98/06278
	APPLICANT MANGEL, et al.	
	International Filing Date October 5, 1998	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
-------------------	---------------	------------	------	-------	----------	----------------------------

Continue on page

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
PS	BA WO92 12149A	23 Jul 1992	PCT			
PS	BB WO92 11259A	9 Jul 1992	PCT			
PS	BC WO92 10494A	25 Jun 1992	PCT			
PS	BD EP0387431 A	19 Sep 1990	EP			
PS	BE WO92 05174A	2 Apr 1992	PCT			
PS	BF EP0377967 A	18 Jul 1990	EP			
PS	BG EP0385722 A	5 Sept 1990	EP			
PS	BH EP0364274 A	18 Apr 1990	EP			
PS	BI EP0357416 A	7 Mar 1990	EP			
PS	BJ EP0347229 A	20 Dec 1989	EP			

Continue on page 2

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

PS	CA	"new product makes a difference", M Magnet, The magazine for Glaxo Wellcome plc staff, page 6, July 1997.
PS	CB	"For Women Only", rubicon, page 9, August 1997.
PS	CC	K. Bardhan et al, "A Double-Blind Placebo-Controlled Study to Evaluate The Irritable Bowel Syndrome (IBS)" Gastroenterology, Vol. 110, No. 4, April 1996, pp A630.
PS	CD	J Foster et al., "Alosetron Slows Colonic Transit in Patients With Irritable Bowel Syndrome (IBS)" Gastroenterology, Vol. 112, 11-14, May 1997, pg. A732.
PS	CE	D.G. Maxton et al., "Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?", ALIMENT. PHARMACOL. THER., Vol. 10, no. 4, Aug 1996, pp 595-599.
PS	CF	J. Zighelboim et al.: "Visceral Perception in Irritable Bowel Syndrome", DIG.SIS.SCI., Vol. 40, No. 4, April 1995, pp 819-827.
PS	CG	C.J. Steadman et al., "Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism with Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study", MAYO CLINIC PROC., Vol. 67, no. 8, August, 1992 pp 732-738.
PS	CH	P.H. Hsyu et al, "Safety and Age, Gender, and Time Dependent Pharmacokinetics of Alosetron", PHARMACEUTICAL RESEARCH, Vol. 12, no. 9 Suppl., Sept. 1995, page S387.
PS	CI	M. Delvaux et al., "Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome", ALIMENT. PHARMACOL. THER., Vol. 12, no. 9, September 1998, pp849-855.
PS	CJ	R. Berkow et al., "The Merck Manual of Diagnosis and Therapy, 16th edition" 1992, MERCK RESEARCH LABORATORIES, Rahway, N.J.

Continue on page 2

EXAMINER Phyllis Spruick	DATE CONSIDERED 8/25/00
-----------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.